JSJun Sugimura

Jun Sugimura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jun Sugimura has a total of 249 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of a new measurement method of indoxyl sulfate in hemodialysis patients

    by Takaya Abe, Mitsutaka Onoda, Tomohiko Matsuura, Jun Sugimura, Wataru Obara, Nariyuki Sasaki, Tetsuo Kato, Kenta Tatsumi, Toru Maruyama

    Indoxyl sulfate (IS) is related to the development of cardiovascular disease and total mortality in dialysis patients. High‐performance liquid chromatography (HPLC) is the conventional measurement approach. However, the HPLC method is difficult to perform in real time. Recently, the IS Assay Kit “NIPRO”, which enables the measuring of total IS by the enzyme method, was developed. This new reagent allows the easy and quick measurement of many samples using the automatic biochemical analyzer. Moreover, it was reported that it demonstrated satisfactory analytical performance. If this enzyme method is useful for measuring IS in hemodialysis, we can expect that the mechanism in which the IS effects adversely on a body as uremic toxins will be clarified. However, the enzyme method is more easily influenced by other coexisting substances. In this study, we have assessed on how the uremic toxins and anticoagulation effect on this new reagent and evaluate whether it can be put into practice effectively for hemodialysis patients. For the enzyme method, accuracy, simultaneous repeatability, linearity, limit of detection, influence of coexisting materials, and correlation with the HPLC method were examined. Accuracy and simultaneous repeatability were satisfactory, and linearity was good. The limit of detection was acceptable, and there was no influence of coexisting materials. With regard to the correlation, the regression equation was y = 0.947X + 7.987 and the correlation coefficient (r) was 0.972. This new reagent showed sufficient fundamental performance and had a good correlation with the conventional HPLC method for assessing the plasma of dialysis patients.


  • Investigation of adherence to sucroferric oxyhydroxide

    by Akito Ito, Takaya Abe, Makoto Takahashi, Naoki Komine, Tomohiko Matsuura, Jun Sugimura, Wataru Obara

    スクロオキシ水酸化鉄 (以下SO) 錠はすぐれたP低下作用を有する一方, チュアブル錠のため堅く噛み砕きづらい特徴も有する. そのため, 高齢患者には内服が困難であるとされている. それに対する対策として錠剤カッターなどを試みられ, さらに2018年12月に新剤型として顆粒分包が発売された. 今回, SO錠が投与されたことがある当院透析患者25名を対象にSO剤の服薬アドヒアランスに関するアンケート調査を行った. またアンケート施行時にSO錠を内服していた患者13例に対して, 錠剤カッターおよび新剤型である顆粒分包への変更による服薬アドヒアランスの変化についても調査した. その結果, チュアブル錠は64%の患者で飲みづらさを感じていた. しかし錠剤カッターの使用により 「飲みやすい」 との回答が0%から54%に上昇し, さらに顆粒分包に変更することにより62%まで上昇した. 以上のように, 医療側の工夫により服薬アドヒアランスを向上させる可能性が示唆された.

  • Protocol for etelcalcetide hydrochloride treatment

    by Akito Ito, Takaya Abe, Shuhei Ishii, Tomohiko Matsuura, Jun Sugimura, Nariyuki Sasaki, Yumiko Takasawa, Tetsuo Kato, Wataru Obara

    エテルカルセチド塩酸塩 (Etel) 開始後の増減については, 各主治医の判断となる. そのため複数の医師による透析管理が行われている施設では, 同一施設内においてもEtelによる二次性副甲状腺機能亢進症 (SHPT) の管理に異なりが生じる可能性がある. 今回, 同一施設内でのEtelによるSHPT管理に異なりが生じないようにEtel投与プロトコールを作成し, その効果について検討した. プロトコールはEtel国内第Ⅲ相長期投与試験に準じ作成した. 22名を対象とし, 研究期間はEtel開始時から開始後28週間目までとした. 研究期間内に, 他因子での死亡2名を含め5名が脱落したが, 17名が研究を完遂した. Etelの投与量は5mgから, 終了時には4.4±1.7mgに有意に低下した (p=0.0084). またintact-PTHが240pg/mL以下に管理された患者数は22名中12名 (54.5%) から終了時には15/17例 (88.2%) と有意に増加した (p=0.0238). 今回作成したプロトコールでは明らかな副作用の出現もなく, 効率的にSHPTの管理が可能であった.


  • Relationship between nocturnal polyuria and non‐dipping blood pressure in male patients with lower urinary tract symptoms

    by Misato Takayama, So Omori, Kazuhiro Iwasaki, Ei Shiomi, Ryo Takata, Jun Sugimura, Takaya Abe, Wataru Obara

    Objective: The aim of the present study was to examine factors of nocturnal polyuria and blood pressure variability in male patients with lower urinary tract symptoms (LUTS) who were treated.Methods: Two hundred and forty‐two male patients with LUTS who were treated recorded frequency volume charts. We investigated their urinary condition and characteristics, medical history, and medications. Thirty‐four of these patients underwent ambulatory blood pressure monitoring (ABPM) for 24 hours to evaluate blood pressure variability.Results: In the present study, 194 patients (80.2%) had nocturia and 136 (56.2%) had nocturnal polyuria (NP). Among patients with nocturia (≥2 voids/night), 130 (67.0%) had nocturnal polyuria, and 26 of those with nocturia (13.4%) had reduced functional bladder capacity. The use of 2 or more antihypertensive medications was significantly higher in the NP than non‐NP group (22.8% vs. 12.3%; P = .035). Significantly more patients in the NP group had non‐dipping blood pressure (P = .037). Non‐dipping blood pressure was considered a potential factor for NP.Conclusion: We suggest that treatment of non‐dipping blood pressure may improve NP.


  • Open Access

    Single-stage laparoscopic surgery for bilateral organ tumors using a transumbilical approach with a zigzag incision: a report of two cases

    by Yoichiro Kato, Renpei Kato, Misato Takayama, Daiki Ikarashi, Mitsutaka Onoda, Tomohiko Matsuura, Mitsugu Kanehira, Ryo Takata, Shigeaki Baba, Toshimoto Kimura, et al.

    Reduced port laparoscopic surgery (RPLS) is comparable to conventional multiport laparoscopic surgery and has the potential to provide improved cosmesis and decreased pain; as such, it satisfies a growing demand for less invasive surgical procedures. Moreover, a zigzag incision of the umbilicus results in a less visible scar in plastic surgery. Here we report a series of two cases with bilateral organ tumors treated by single-stage RPLS using a combination of a transumbilical approach and a zigzag incision. Case 1: A 63-year-old man was diagnosed with right renal cell carcinoma (RCC) (clear cell carcinoma, pT1a, venous invasion (−)) and a splenic tumor (cavernous hemangioma). Case 2: An 84-year-old woman was diagnosed with concurrent left RCC (clear cell carcinoma, pT1b, 65 × 65 mm, venous invasion (+)) and ascending colon cancer (adenocarcinoma pT3 with no nodal involvement (0/48)). The perioperative course was uneventful in both cases. However, an additional incision was required in Case 2 for specimen excision. Therefore, the scars were more obvious in Case 2 than in Case 1. Although more cases are required to evaluate the superiority of this technique, this novel procedure could be considered for patients with bilateral lesions.


  • Open Access

    Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma

    by Daiki Ikarashi, Yoichiro Kato, Hirokatsu Katagiri, Takeshi Takahara, Noriyuki Uesugi, Ei Shiomi, Jun Sugimura, Hiroyuki Nitta, Tamotsu Sugai, Wataru Obara

    Here, we report a case of a 68‐year‐old woman with cT4N0M1 (liver invasion and multiple lung metastases) metastatic renal cell carcinoma. We could carry out less invasive nephrectomy with partial hepatectomy because nivolumab administration as second‐line therapy reduced the primary tumor remarkably. To the best of our knowledge, this is the first report of the use of nivolumab before carrying out surgery, and histological findings showed a pathological complete response.


  • Pelvic Artery Calcification Score Is a Marker of Vascular Calcification in Male Hemodialysis Patients

    by Tomohiko Matsuura, Takaya Abe, Mitsutaka Onoda, Daiki Ikarashi, Jun Sugimura, Toshiaki Komaki, Nariyuki Sasaki, Yumiko Takasawa, Tetsuo Kato, Kunihiro Yoshioka, et al.

    Patients who undergo hemodialysis often suffer from cardiovascular disease (CVD), and evaluation of coronary artery calcification is extremely important. These evaluations are typically conducted using a noninvasive method including electron beam computed tomography (CT) or multi‐detector CT, and the Agatston method to calculate the coronary artery calcification score (CACS). However, it is difficult to use for patients undergoing dialysis. Because patients undergoing dialysis is too strong in coronary artery calcification, and results become incorrect. Therefore, we were looking for a calcified evaluation place peculiar to a patients undergoing dialysis. We obtained pelvic artery calcification scores (PACS) using a 64‐row multi‐slice CT to assess the presence of calcification within a triangular space bordered by bordered by osseous structure. We used the Agatston method to calculate PACS. We compared male patients undergoing dialysis with male patients with normal renal function. Patients undergoing hemodialysis had a significantly higher incidence of pelvic artery calcification than normal controls (79.7% vs. 5.5%). In the dialysis group, CACS was 1660.2 (0–9056.1), and PACS was 48.8 (0–2943.1). We found a correlation between PACS and CACS and between PACS and dialysis period. We found penile artery calcification in male patients undergoing hemodialysis was more than normal controls, and it was possible to quantify PACS using the Agatston method. This study suggested the possibility that PACS became the vascular calcification evaluation method of the hemodialysis patient.


  • COMPLETE RESECTION OF URACHAL CARCINOMA WITH SIGMOID COLON INVASION AFTER FOLFOX CHEMOTHERAPY: A CASE REPORT

    by Akito Ito, Ryo Takata, Teppei Matsuo, Toshimoto Kimura, Kouki Otsuka, Shuhei Ishii, Suguru Tokiwa, Susumu Tanji, Jun Sugimura, So Omori, et al.

    症例は45歳男性.臍部からの膿汁排出と下腹部痛を主訴に受診した.膀胱鏡およびCT検査で臍部から膀胱頂部に連続し膀胱内腔に突出する不整な腫瘤を認め,S状結腸への浸潤も認めた.生検で腺癌を認め尿膜管癌stage IIIDと診断した.オキサリプラチンと5-フルオロウラシルを含む多剤併用化学療法であるFOLFOX療法を開始したところ,2コース後から著明な縮小を認め,8コース後には約80%の縮小を得た.計11コース施行後に根治手術が可能と判断し,尿膜管癌摘除およびS状結腸合併切除術を施行した.治療後30カ月経過した現在まで再発は認めていない.尿膜管癌は発見時には進行癌であることが多く,治療は手術による腫瘍の完全切除以外は未確立で予後不良とされる.今回われわれは,当初根治術困難と判断されたS状結腸浸潤を伴う尿膜管癌に対してFOLFOX化学療法が奏効し,完全摘除しえた一例を経験したので報告する.


  • Non-machinery dialysis that achieves blood purification therapy without using full-scale dialysis machines

    by Takaya Abe, Mistutaka Onoda, Tomohiko Matsuura, Jun Sugimura, Wataru Obara, Toshiya Sato, Mihoko Takahashi, Kenta Chiba, Tomiya Abe

    An electrical or water supply and a blood purification machine are required for renal replacement therapy. There is a possibility that acute kidney injury can occur in large numbers and on a wide scale in the case of a massive earthquake, and there is the potential risk that the current supply will be unable to cope with acute kidney injury cases. However, non-machinery dialysis requires exclusive circuits and has the characteristic of not requiring the full-scale dialysis machines. We performed perfusion experiments that used non-machinery dialysis and recent blood purification machines in 30-min intervals, and the effectiveness of non-machinery dialysis was evaluated by the assessing the removal efficiency of potassium, which causes lethal arrhythmia during acute kidney injury. The non-machinery dialysis potassium removal rate was at the same level as continuous blood purification machines with a dialysate flow rate of 5 L/h after 15 min and continuous blood purification machines with a dialysate flow rate of 3 L/h after 30 min. Non-machinery dialysis required an exclusive dialysate circuit, the frequent need to replace bags, and new dialysate exchanged once every 30 min. However, it can be seen as an effective renal replacement therapy for crush-related acute kidney injury patients, even in locations or facilities not having the full-scale dialysis machines.


  • Impact of four loci on serum tamsulosin hydrochloride concentration

    by Ryo Takata, Koichi Matsuda, Jun Sugimura, Wataru Obara, Tomoaki Fujioka, Koji Okihara, Natsuki Takaha, Tsuneharu Miki, Shingo Ashida, Keiji Inoue, et al.

    Tamsulosin hydrochloride is one of the most potent drugs for treatment of benign prostatic hyperplasia (BPH), however, the efficacy of tamsulosin hydrochloride varies among individuals. In this study, we measured the maximum serum concentration (Cmax) of tamsulosin hydrochloride in 182 of BPH patients and found remarkable individual variability. To investigate the genetic factors that regulate pharmacokinetics of tamsulosin hydrochloride, we conducted a genome-wide association study in these 182 BPH patients. As a result, rs16902947 on chromosome 5p13.2, rs7779057 on 7q22.3, rs35681285 on 7p21.2 and rs2122469 on 8p21.3 indicated possible associations with Cmax of tamsulosin hydrochloride (P=1.29 × 10−7, 2.15 × 10−7, 4.35 × 10−7 and 7.03 × 10−7, respectively), although these single-nucleotide polymorphisms (SNPs) did not reach the genome-wide significance threshold after Bonferroni correction. As these associated SNPs showed additive effects on serum tamsulosin hydrochloride concentration, we defined the ‘Cmax prediction index’ based on genotypes of these SNPs. This index clearly associated with Cmax values (P=4.5 × 10−6), indicating the possible roles of these four variants in tamsulosin hydrochloride pharmacokinetics. Our findings would partially explain the variability of the response to the tamsulosin hydrochloride treatment.